Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.
Department of Pathology, St. Olav's Hospital, Trondheim, Norway.
PLoS One. 2023 Jun 27;18(6):e0287608. doi: 10.1371/journal.pone.0287608. eCollection 2023.
P21-activated kinase 1 (PAK1) is known to be overexpressed in several human tumour types, including breast cancer (BC). It is located on chromosome 11 (11q13.5-q14.1) and plays a significant role in proliferation in BC. In this study we aimed to assess PAK1 gene copy number (CN) in primary breast tumours and their corresponding lymph node metastases, and associations between PAK1 CN and proliferation status, molecular subtype, and prognosis. In addition, we aimed to study associations between CNs of PAK1 and CCND1. Both genes are located on the long arm of chromosome 11 (11q13).
Fluorescence in situ hybridization for PAK1 and Chromosome enumeration probe (CEP)11 were used on tissue microarray sections from a series of 512 BC cases. Copy numbers were estimated by counting the number of fluorescent signals for PAK1 and CEP11 in 20 tumour cell nuclei. Pearson's x2 test was performed to assess associations between PAK1 CN and tumour features, and between PAK1 and CCND1 CNs. Cumulative risk of death from BC and hazard ratios were estimated in analysis of prognosis.
We found mean PAK1 CN ≥4<6 in 26 (5.1%) tumours, and CN ≥ 6 in 22 (4.3%) tumours. The proportion of cases with copy number increase (mean CN ≥4) was highest among HER2 type and Luminal B (HER2-) tumours. We found an association between PAK1 CN increase, and high proliferation, and high histological grade, but not prognosis. Of cases with PAK1 CN ≥ 6, 30% also had CCND1 CN ≥ 6.
PAK1 copy number increase is associated with high proliferation and high histological grade, but not with prognosis. PAK1 CN increase was most frequent in the HER2 type and Luminal B (HER2-) subtype. PAK1 CN increase is associated with CN increase of CCND1.
已发现 P21 激活激酶 1(PAK1)在包括乳腺癌(BC)在内的几种人类肿瘤类型中过表达。它位于 11 号染色体(11q13.5-q14.1)上,在 BC 中增殖中发挥重要作用。在这项研究中,我们旨在评估原发性乳腺癌肿瘤及其相应的淋巴结转移中的 PAK1 基因拷贝数(CN),以及 PAK1 CN 与增殖状态、分子亚型和预后之间的关联。此外,我们旨在研究 PAK1 和 CCND1 的 CN 之间的关联。这两个基因都位于 11 号染色体的长臂(11q13)上。
使用组织微阵列切片上的荧光原位杂交技术对来自 512 例 BC 病例的 PAK1 和染色体计数探针(CEP)11 进行检测。通过对 20 个肿瘤细胞核中的 PAK1 和 CEP11 的荧光信号数量进行计数来估计拷贝数。使用 Pearson x2 检验来评估 PAK1 CN 与肿瘤特征之间的关联,以及 PAK1 与 CCND1 CN 之间的关联。在分析预后时,估计了死于 BC 的累积死亡风险和危险比。
我们发现 26 例(5.1%)肿瘤中 PAK1 CN≥4<6,22 例(4.3%)肿瘤中 PAK1 CN≥6。在 HER2 型和 Luminal B(HER2-)型肿瘤中,具有拷贝数增加(平均 CN≥4)的病例比例最高。我们发现 PAK1 CN 增加与高增殖和高组织学分级相关,但与预后无关。在 PAK1 CN≥6 的病例中,有 30%的病例也有 CCND1 CN≥6。
PAK1 拷贝数增加与高增殖和高组织学分级相关,但与预后无关。PAK1 CN 增加最常见于 HER2 型和 Luminal B(HER2-)亚型。PAK1 CN 增加与 CCND1 CN 增加相关。